Home›The Treatise›Chapters›Chapter 11
Tratado de Cirurgia da Coluna Vertebral
SECTION 1 • Basic Concepts
Chapter11

Spinal Dysraphism — Neural Tube Defects

Vancouver: Carvalho MV📖 Pages: 135-146
Full reading of this chapter is available exclusively in the printed edition of the Treatise.
Sec. 1Basic Concepts
Cap. 11Clinical Chapter
1authors
Português
Español
English
Referênciasscientific citations
📑

Chapter Summary

• Context: Neural tube defects (NTDs) result from failure of normal embryonic neural tube closure during the third and fourth weeks of gestation, encompassing cranial and spinal anomalies with varying severity of neurological, musculoskeletal, and urological impairment. Within this spectrum, spinal dysraphism designates congenital midline dorsal malformations involving skin, paraspinal muscles, vertebral arches, meninges, and neuroectodermal tissues; strictly speaking, spina bifida describes the osseous failure of posterior neural arch fusion. The chapter differentiates open spinal dysraphisms (spina bifida aperta, myelomeningocele, myelocele, rachischisis)—caused by failure of primary neurulation where neural placodes lie exposed to amniotic fluid—from closed spinal dysraphisms (spina bifida occulta, lipomyelomeningocele, dorsal dermal sinus, diastematomyelia, tight filum terminale)—derived primarily from abnormal secondary neurulation or premature dysjunction, often associated with a subcutaneous mass and spinal cord tethering (tethered cord syndrome). The etiology is complex and multifactorial, arising from interactions between genetic susceptibility (folate-metabolism gene variants such as MTHFR), maternal nutritional deficiencies (folate, inositol, vitamin B12), pre-existing maternal disorders (diabetes mellitus, obesity), antiepileptic medications (valproic acid, carbamazepine), and environmental teratogens. Management spans the lifecycle: periconceptional folic acid fortification, prenatal maternal serum alpha-fetoprotein (MSAFP) and ultrasound screening, in utero fetal endoscopic/open surgical repair, neonatal closure within 48 hours, and lifelong multidisciplinary neurosurgical, urological, and orthopedic surveillance.
• Chapter Objective: To present the embryological development and classification of neural tube defects, distinguishing primary from secondary neurulation and open from closed spinal dysraphisms. The reader should be able to recognize nutritional, genetic, metabolic, pharmaceutical, and environmental risk factors; understand preventive strategies and prenatal/postnatal intervention modalities; and identify clinical manifestations, tethered cord syndrome, and long-term multidisciplinary care requirements across pediatric and adult life.
• Embryology: Primary vs. Secondary NeurulationPrimary neurulation (embryonic days 18–28) forms the brain and spinal cord down to the upper sacral level (S1–S2): the neural plate invaginates, elevates into neural folds, and fuses bidirectionally from multiple initiation sites, with the anterior neuropore closing at day 25 and posterior neuropore closing at day 28. Disruption of primary neurulation causes open NTDs with exposed placodes. Secondary neurulation (days 28–48) forms the lower sacrococcygeal segments through cavitation and canalization of the caudal cell mass within the tail bud, followed by retrogressive differentiation into the conus medullaris, ventriculus terminalis, and filum terminale. Errors in secondary neurulation produce closed dysraphisms and tethering anomalies.
• Classification: Open vs. Closed DysraphismsOpen spinal dysraphisms (spina bifida aperta) feature neural tissue exposed to amniotic fluid with CSF leakage; myelomeningocele (MMC, 98% of open cases) presents as a dorsal fluid-filled sac containing neural elements, universally accompanied by Chiari II malformation, obstructive hydrocephalus, lower extremity paraparesis, neurogenic bladder, and bowel dysfunction. Closed spinal dysraphisms are covered by intact skin. They are subclassified into: 1) With a subcutaneous mass: lipomyelomeningocele, lipomyelocele, meningocele, myelocystocele; and 2) Without a subcutaneous mass: diastematomyelia (split cord malformation type I with osseous/cartilaginous spur and type II with fibrous septum), dorsal dermal sinus tract, caudal regression syndrome, and tight filum terminale.
• Cutaneous Stigmata and Tethered Cord SyndromeClosed dysraphisms often declare themselves via midline cutaneous markers: hypertrichosis (faun tail nevus), subcutaneous lipoma, sacral dimple (especially >5 mm deep or >2.5 cm above anal verge), hemangioma, capillary telangiectasia, dermal sinus pit, or aplasia cutis. Tethered cord syndrome occurs when inelastic structures (lipoma, tight thickened filum >2 mm, bony spur, dura) anchor the conus medullaris below the L2 level, causing progressive mechanical stretch and ischemic traction injury during somatic spinal growth. Symptoms include progressive lower extremity weakness, gait deterioration, foot deformities (cavus foot, clubfoot), back and leg pain, progressive scoliosis, and worsening bladder/bowel incontinence.
• Etiology and Periconceptional PreventionEtiology is multifactorial: genetic mutations in one-carbon folate metabolism (MTHFR C677T, DHFR, MTHFD1) interact with environmental triggers. Maternal diabetes increases NTD risk 2- to 4-fold, maternal obesity increases risk 1.5- to 3-fold, and maternal valproic acid therapy carries a 1–2% incidence of lumbar myelomeningocele. Periconceptional folic acid supplementation (0.4 mg/day in low-risk women and 4.0–5.0 mg/day in women with previous affected pregnancy or high risk, initiated at least 1–3 months prior to conception and continued through the first trimester) reduces NTD occurrence and recurrence by up to 70%.
• Prenatal Repair, Neonatal Surgery, and Long-Term CarePrenatal screening utilizes mid-trimester maternal serum alpha-fetoprotein (elevated in open NTDs), detailed fetal ultrasonography (lemon sign, banana sign, ventriculomegaly), and ultrafast fetal MRI. The Management of Myelomeningocele Study (MOMS trial) demonstrated that in utero fetal surgical repair before 26 weeks gestation significantly decreases the need for hydrocephalus shunting, improves motor function, and reverses hindbrain herniation (Chiari II) compared to standard postnatal repair. For postnatally delivered infants, airtight watertight multilayer surgical closure within 24–48 hours is mandatory to prevent ascending ventriculitis/meningitis and preserve neurological function. Lifelong multidisciplinary management encompasses ventriculoperitoneal shunt/ETV surveillance, clean intermittent catheterization (CIC) for neurogenic bladder, orthopedic correction of equinovarus/hip dislocation, and scoliosis management.
• Clinical Application: In clinical practice, neonatal evaluation begins with distinguishing open from closed lesions. In open myelomeningocele, maintain the infant prone, cover the placode with sterile warm saline gauze, avoid latex exposure, administer broad-spectrum antibiotics, and perform definitive surgical reconstruction within 24–48 hours. In newborns presenting with midline cutaneous markers (hypertrichosis, lipoma, deep sinus pit), screening spinal ultrasound (before 3–4 months of age) or MRI is mandatory to evaluate conus level, cord tethering, and intradural lipoma before irreversible neurological decline occurs. In children presenting with progressive cavus foot, gait disturbance, unprovoked back/leg pain, progressive scoliosis, or new-onset urinary incontinence, urgent whole-spine MRI must be performed to diagnose tethered cord syndrome, diastematomyelia, or syringomyelia. Surgical untethering (resection of thickened filum terminale, excision of osseous septum, or lipoma debulking) prevents irreversible neurological and urological deterioration.
🏷️

Keywords

Preferred DeCS/MeSH Descriptors:
Neural Tube DefectsSpinal DysraphismMeningomyeloceleSpina Bifida OccultaTethered Cord SyndromeFolic AcidPrenatal DiagnosisFetal Therapies
⭐

Why this chapter matters

This chapter connects early embryonic neurulation failure to lifelong multi-system challenges. Distinguishing primary from secondary neurulation clarifies why open lesions present with exposed neural tissue and Chiari II malformation, whereas closed dysraphisms remain occult until progressive gait disturbances, neurogenic bladder, or spinal deformities manifest during pediatric growth spurts. Understanding this embryological and clinical spectrum guides periconceptional prevention, prenatal counseling, fetal surgery indications, and adult tethered cord management, preventing diagnostic delay and permanent neurological loss.

“Neural tube defects represent a developmental spectrum governed by the timing and level of neurulation failure. Their clinical presentation reflects complex gene-environment interactions that impact the patient from the fetal period through adulthood. Periconceptional folic acid prevention, accurate prenatal classification, timely fetal or neonatal surgical repair, and lifelong multidisciplinary surveillance form the foundational pillars of comprehensive care.”
✨

Chapter Highlights

🌐
Card 1 — Core Concept
Primary vs. Secondary Neurulation

Primary neurulation failure (days 18–28) causes open defects (myelomeningocele) with exposed neural placodes, CSF leak, and Chiari II malformation. Secondary neurulation failure (days 28–48) causes closed dysraphisms (lipomyelomeningocele, tight filum), covered by skin and presenting with cord tethering.

🩺
Card 2 — Clinical Decision
Investigate Cutaneous Midline Markers

Midline lumbar cutaneous stigmata (faun tail hypertrichosis, subcutaneous lipoma, deep dimple, dermal sinus) are hallmarks of occult spinal dysraphism. Obtain screening spinal ultrasound or MRI before 3–4 months of age to diagnose tethered cord before permanent neurological or sphincter loss occurs.

📐
Card 3 — Key Pearl / Warning
Periconceptional Folic Acid Prevents NTDs

Supplementing folic acid (0.4 mg/day standard; 4.0–5.0 mg/day for previous NTD, diabetes, or antiepileptic therapy) starting at least 1–3 months before conception reduces neural tube defect occurrence and recurrence by up to 70%. In utero fetal repair before 26 weeks improves motor outcomes and reverses Chiari II.

📑

How to Cite this Chapter (Vancouver Format)

Official bibliographic indexing and citation guidelines
📖 Pages: 135-146Vancouver Style
Authors (Vancouver):Carvalho MV

Carvalho MV. Disrafismo espinhal – defeitos do tubo neural. In: Pudles E, Defino H, Risso M, editors. Tratado de Cirurgia da Coluna Vertebral (Treatise of Spine Surgery). 1st ed. Rio de Janeiro: Dilivros Editora; 2026. p. 135-146.

ISBN: 978-85-8053-292-0 • 1.ª Edição • Dilivros Editora
📚

Bibliographic References

1. Greene ND, Copp AJ. Neural tube defects. Annu Rev Neurosci. 2014;37:221-42.
2. Yacob A, Carr CJ, Foote J, Scullen T, Werner C, Mathkour M, et al. The global burden of neural tube defects and disparities in neurosurgical care. World Neurosurg. 2021;149:e803-e820.
3. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349-64.
4. Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia. 2003;44 Suppl 3:4-13.
5. Chen CP. Chromosomal abnormalities associated with neural tube defects (I): full aneuploidy. Taiwan J Obstet Gynecol. 2007;46:325-35.
6. Chen CP. Syndromes, disorders, and maternal risk factors associated with neural tube defects (II). Taiwan J Obstet Gynecol. 2008;47:10-17.
7. Avagliano, Massa V, George TM, Qureshy S, Bulfamante GP, Finnell RH. Overview on neural tube defects: from development to physical characteristics. Birth Defect Res. 2019;111:1455-67.
8. Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 2013;12:799-810.
9. Harris MJ, Juriloff DM. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res A Clin Mol Teratol. 2010;88:653-69.
10. Nakatsu T, Uwabe C, Shiota K. Neural tube closure in humans initiates at multiple sites: evidence from human embryos and implications for the pathogenesis of neural tube defects. Anat Embryol (Berl). 2000;201:455-66.
11. O’Rahilly R, Müller F. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology. 2002;65:162-70.
12. Lew SM, Kothbauer KF. Tethered cord syndrome: an updated review. Pediatr Neurosurg. 2007;43:236-48.
13. Juriloff DM, Harris MJ. Hypothesis: the female excess in cranial neural tube defects reflects an epigenetic drag of the inactivating X chromosome on the molecular mechanisms of neural fold elevation. Birth Defects Res A Clin Mol Teratol. 2012;94:849-55.
14. Agopian, Tinker SC, Lupo PJ, Canfield MA, Mitchell LE; National Birth Defects Prevention Study. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res A Clin Mol Teratol. 2013;97:42-6.
15. Pietrzik K, Bailey L, Shane B. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010;49:535-48.
16. Copp AJ, Greene ND. Genetics and development of neural tube defects. J Pathol. 2010;220:217-30.
17. Bortolus, Filippini F, Cipriani S, Trevisanuto D, Cavallin F, Zanconato G, et al. Efficacy of 4.0 mg versus 0.4 mg folic acid supplementation on the reproductive outcomes: a randomized controlled trial. Nutrients. 2021;13:4422.
18. Wang L, Chang S, Wang Z, Wang S, Huo J, Ding G, et al. Altered GNAS imprinting due to folic acid deficiency contributes to poor embryo development and may lead to neural tube defects. Oncotarget. 2017;8:110797-110810.
19. Harris MJ, Juriloff DM. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res A Clin Mol Teratol. 2010;88:653-69.
20. Lei, Fathe K, McCartney D, Zhu H, Yang W, Ross ME, et al. Rare LRP6 variants identified in spina bifida patients. Hum Mutat. 2015;36:342-49.
21. Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet. 2012;158A:2071-90.
22. Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology. 2005;16:216-19.
23. Abdel-Shafy HI, Mansour MSM. A review on polycyclic aromatic hydrocarbons: source, environmental impact, effect on human health and remediation. Egypt J Pet. 2016;25:107-23.
24. Li Z, Zhang L, Ye R, Pei L, Liu J, Zheng X, et al. Indoor air pollution from coal combustion and the risk of neural tube defects in a rural population in Shanxi Province, China. Am J Epidemiol. 2011;174:451-58.
25. Langlois PH, Hoyt AT, Lupo PJ, Lawson CC, Waters MA, Desrosiers TA, et al. Maternal occupational exposure to polycyclic aromatic hydrocarbons and risk of neural tube defect-affected pregnancies. Birth Defects Res A Clin Mol Teratol. 2012;94:693-700.
26. Wang B, Jin L, Ren A, Yuan Y, Liu J, Li Z, et al. Levels of polycyclic aromatic hydrocarbons in maternal serum and risk of neural tube defects in offspring. Environ Sci Technol. 2015;49:588-96.
27. Patel AB, Shaikh S, Jain KR, Desai C, Madamwar D. Polycyclic aromatic hydrocarbons: sources, toxicity, and remediation approaches. Front Microbiol. 2020;11:562813.
28. Amitai Y, Koren G. High risk for neural tube defects; the role of arsenic in drinking water and rice in Asia. Med Hypotheses. 2018;119:88-90.
29. Wlodarczyk BJ, Cabrera RM, Hill DS, Bozinov D, Zhu H, Finnell RH. Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. Neurotoxicology. 2006;27:547-57.
30. Mazumdar M. Does arsenic increase the risk of neural tube defects among a highly exposed population? A new case-control study in Bangladesh. Birth Defects Res. 2017;109:92-8.
31. Kalra, Dewan P, Batra P, Sharma T, Tyagi V, Banerjee BD. Organochlorine pesticide exposure in mothers and neural tube defects in offsprings. Reprod Toxicol. 2016;66:56-60.
32. Brender JD, Felkner M, Suarez L, Canfield MA, Henry JP. Maternal pesticide exposure and neural tube defects in Mexican Americans. Ann Epidemiol. 2010;20:16-22.
33. Baldacci S, Gorini F, Santoro M, Pierini A, Minichilli F, Bianchi F. Environmental and individual exposure and the risk of congenital anomalies: a review of recent epidemiological evidence. Epidemiol Prev. 2018;42(3-4 Suppl 1):1-34.
34. Suarez L, Felkner M, Brender JD, Canfield M, Zhu H, Hendricks KA. Neural tube defects on the Texas-Mexico border: what we’ve learned in the 20 years since the Brownsville Cluster. Birth Defects Res A Clin Mol Teratol. 2012;94:882-92.
35. Shaw GM, Wasserman CR, O’Malley CD, Nelson V, Jackson RJ. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology. 1999;10:60-6.
36. Balarajan R, McDowall M. Congenital malformations and agricultural workers. Lancet. 1983;1:1112-13.
37. Zhang J, Chen FZ, Gao Q, Sun JH, Tian GP, Gao YM. Hyperthermia induces upregulation of connexin43 in the golden hamster neural tube. Birth Defects Res A Clin Mol Teratol. 2012;94:16-21.
38. Harvey MA, McRorie MM, Smith DW. Suggested limits to the use of the hot tub and sauna by pregnant women. Can Med Assoc J. 1981;125:50-3.
39. Lundberg YW, Wing MJ, Xiong W, Zhao J, Finnell RH. Genetic dissection of hyperthermia-induced neural tube defects in mice. Birth Defects Res A Clin Mol Teratol. 2003;67:409-13.
40. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163:978-85.
41. Gilboa SM, Broussard CS, Devine OJ, Duwe KN, Flak AL, Boulet SL, et al. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet C Semin Med Genet. 2011;157:234-46.
42. Interrante JD, Ailes EC, Lind JN, Anderka M, Feldkamp ML, Werler MM, et al. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011. Ann Epidemiol. 2017;27:645-653.e2.
43. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-37.
44. Sudiwala, Palmer A, Massa V, Burns AJ, Dunlevy LPE, de Castro SCP, et al. Cellular mechanisms underlying Pax3-related neural tube defects and their prevention by folic acid. Dis Model Mech. 2019;12:dmm042234.
45. Barbera JP, Rodriguez TA, Greene ND, Weninger WJ, Simeone A, Copp AJ, et al. Folic acid prevents exencephaly in Cited2 deficient mice. Hum Mol Genet. 2002;11:283-93.
46. van Straaten HW, Copp AJ. Curly tail: a 50-year history of the mouse spina bifida model. Anat Embryol (Berl). 2001;203:225-37.
47. De Castro SC, Leung KY, Savery D, Burren K, Rozen R, Copp AJ, et al. Neural tube defects induced by folate deficiency in mutant curly tail (Grhl3) embryos are associated with alteration in folate one-carbon metabolism but are unlikely to result from diminished methylation. Birth Defects Res A Clin Mol Teratol. 2010;88:612-18.
48. Greene ND, Leung KY, Copp AJ. Inositol, neural tube closure and the prevention of neural tube defects. Birth Defects Res. 2017;109:68-80.
49. Cockroft DL, Brook FA, Copp AJ. Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro. Teratology. 1992;45:223-32.
50. Russo M, Forte G, Montanino Oliva M, Laganà AS, Unfer V. Melatonin and myo-inositol: supporting reproduction from the oocyte to birth. Int J Mol Sci. 2021;22:8433.
51. D’Souza SW, Copp AJ, Greene NDE, Glazier JD. Maternal inositol status and neural tube defects: a role for the human yolk sac in embryonic inositol delivery? Adv Nutr. 2021;12:212-22.
52. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021;22:10575.
53. Rose NC, Mennuti MT. Fetal neural tube defects: diagnosis, management, and treatment. Carlisle (UK): The Foundation for The Global Library of Women’s Medicine; 2009.
54. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15:36-45.
55. Gupta DK, Sharma S, Venugopal P, Kumar L, Mohanty S, Dattagupta S. Stem cells as a therapeutic modality in pediatric malformations. Transplant Proc. 2007;39:700-2.
56. Mitrecic, Nicaise C, Klimaschewski L, Gajovic S, Bohl D, Pochet R. Genetically modified stem cells for the treatment of neurological diseases. Front Biosci (Elite Ed). 2012;4:1170-81.
57. Isaković J, Šimunić I, Jagečić D, Hribljan V, Mitrečić D. Overview of neural tube defects: gene-environment interactions, preventative approaches and future perspectives. Biomedicines. 2022;10:965.
58. Godzik, Ravindra VM, Ray WZ, Eskandari R, Dailey AT. Primary repair of open neural tube defect in adulthood: case example and review of management strategies. Spine J. 2015;15:e57-e63.
59. Rossi A, Cama A, Tortori-Donati P. Spinal dysraphism: a review of neurological features. Paediatr Neuroradiol. 2000;42:471-91.
60. Youmans JR, editor. Neurological surgery. 2nd ed. Philadelphia: WB Saunders; 1982. p. 1.
Episode 06 – Early-Onset Scoliosis
Scheduled Premiere
Exclusive Premiere • Wednesday, October 07 at 9:00 PM (BRT)
Wednesday, October 07 at 9:00 PM (BRT)
The live countdown will be activated on the eve of the premiere.

The full videocast will premiere automatically in this player on Wednesday, 10/07 at 6:00 PM (BRT).

Also premiering on Spotify
Treatise in Debate

Official videocast derived from the treatise chapters.

Episode 06 – Early-Onset Scoliosis

Lungs and the Growing Spine: thoracic development, C-EOS classification, and growth-friendly surgical techniques